Business Numinus gets new biosecurity licence to expand psilocybin research CEO Payton Nyquvest says the authorization moves his firm closer to developing medicines at scale to support psychedelic-assisted therapy Nick LabaMarch 14, 2022
Business Numinus submits novel psilocybe formulation for clinical trial If approved, it will mark the firm's first independent clinical trial with a proprietary extract Nick LabaJanuary 14, 2022
Business Numinus develops in-house tests to detect compounds in psychedelic mushrooms The methods will be available as part of third-party client services Nick LabaNovember 29, 2021
Canada Numinus to test natural psilocybin safety in Phase 1 trial Study aims to prove safety of psilocybe mushrooms so Canadian regulators can expand access to psychedelic therapy Jared GnamApril 27, 2021
Investment Ideas MagicMed aims to mainstream psychedelic therapy with world’s largest ‘Psybrary’ Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine Jared GnamDecember 1, 2020
Psychedelics Numinus licensed by Health Canada to extract and research psilocybin Extracting psilocybin from magic mushrooms will be cheaper than current method of creating synthetic compound for research, says company Michelle GamageJune 12, 2020
Medical and Pharmaceutical Canada could regulate psychedelic therapy within few years, bets company Numinus Wellness goes public on the prediction that regulation is coming Michelle GamageMay 22, 2020